Page 184 - Aet News Today

Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting. For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process.

Talkspace's new product, Talkspace Engage, aims to help employers promote their mental health benefits to their employees. It allows employers to easily share mental health resources and virtual classes led by Talkspace clinicians.

Moderna’s mRNA vaccine for influenza has early data from a pivotal study showing it met trial goals assessing immune response against the more common strains of the virus, but missed against two less common types. A separate and ongoing Phase 3 study is assessing efficacy.

Panelists at a recent healthcare conference expressed optimism about the automation technology that health plans, pharmacy benefit managers and providers can adopt to facilitate real-time data sharing. They said that such technology has potential to improve medication adherence, reduce costs and save time for both providers and payers.

Making operational changes to ease the unpredictable nature of respiratory season is the right thing to do for staff, for patients, and for the business. Digital solutions and better processes allow staff to work smarter and faster and prepare them for high-volume days ahead of time so they feel in control.

The increased demand for stimulant medications such as Adderall for ADHD is not the result of abuse or misdiagnosis but is caused by a previously unmet need for treatment of ADHD, which telepsychiatry finally satisfied.

Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product.

BlueCross BlueShield of Tennessee's health equity report analyzed disparities in behavioral health, cancer, child and adolescent care, chronic condition management, Covid-19 and maternal health.

Grifols said the layoffs sparked by its restructuring represent just 8% of its workforce. But the cuts will happen mainly in the Barcelona-based company’s U.S. plasma operations, source of most of the plasma that is the basis for its biologic medicines.

Pharma players, now more than ever, need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.